Home / Research library / Fasoracetam Powder
Fasoracetam Powder: molecular data, studies & sources
Fasoracetam Powder is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C10H16N2O2
- Molecular weight (MW)
- 196.25 g/mol
- PubChem compound ID
- 198695
- Record title
- Fasoracetam
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 198695 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- (5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one
- InChIKey
- GOWRRBABHQUJMX-MRVPVSSYSA-N
- SMILES
- C1CCN(CC1)C(=O)[C@H]2CCC(=O)N2
Identifiers
- PubChem CID
- 198695
- CAS Registry Number
- 110958-19-5via ChemIDplus, EPA DSSTox, FDA GSRS
- FDA UNII
- 42O8UF5CJB
- ChEMBL ID
- CHEMBL2106179
- InChIKey
- GOWRRBABHQUJMX-MRVPVSSYSA-N
- Wikidata
- Q5436839
Other names and development codes: AEVI-001 · LAM-105 ANHYDROUS · NFC-1 ANHYDROUS · NS-105 · LAM-105
CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 196.1212 Da |
|---|---|
| Heavy atoms | 14 |
| Hydrogen-bond donors | 1 |
| Hydrogen-bond acceptors | 2 |
| Rotatable bonds | 1 |
| Topological polar surface area | 49.4 Ų |
| Calculated logP (Crippen) | 0.28 |
| Rings | 2 |
| Stereocenters | 1 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
US regulatory status & drug development
Drug development record (ChEMBL)
Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.
- ChEMBL ID
- CHEMBL2106179
- Modality
- Small molecule
- Highest clinical stage
- Phase 2
- Record name
- FASORACETAM
Synonyms, codes and trade names
- Synonyms and development codes
- AEVI-001 · AEVI001 · Fasoracetam · LAM-105 · LAM-105 ANHYDROUS · LAM105 ANHYDROUS · NFC-1 ANHYDROUS · NFC1 ANHYDROUS · NS-105 · NS105
Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL2106179 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-07
Registered clinical trials
Studies registered on ClinicalTrials.gov that list Fasoracetam as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
6 registered studies matched, 3 with results posted on ClinicalTrials.gov.
- By highest phase
- Phase 3 · 1Phase 2 · 2Phase 1 · 3
- By registry status
- Completed · 6
| Study | Phase · status | Conditions | Sponsor · size |
|---|---|---|---|
| PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR MutationsNCT03609619 · start 2018-08-17 · primary completion 2018-11-23 | Phase 2CompletedResults posted 2019-07-16 | Attention Deficit Hyperactivity Disorder | Aevi Genomic Medicine, LLC, a Cerecor company109 participants |
| PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR MutationsNCT03265119 · start 2017-08-28 · primary completion 2018-09-24 | Phase 2CompletedResults posted 2019-07-16 | Attention Deficit Hyperactivity Disorder | Aevi Genomic Medicine, LLC, a Cerecor company69 participants |
| Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHDNCT03006367 · start 2017-01-07 · primary completion 2017-02-26 | Phase 1Completed | Attention Deficit Disorder With Hyperactivity | Aevi Genomic Medicine, LLC, a Cerecor company32 participants |
| Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric ConditionsNCT02895906 · start 2016-11-28 · primary completion 2017-04-13 | Phase 1Completed | 22q11.2 Deletion Syndrome | Aevi Genomic Medicine, LLC, a Cerecor company2 participants |
| Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHDNCT02777931 · start 2016-06 · primary completion 2017-02-10 | Phase 2 / Phase 3CompletedResults posted 2018-03-29 | Attention Deficit Disorder With Hyperactivity | Aevi Genomic Medicine, LLC, a Cerecor company101 participants |
| Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity DisorderNCT02286817 · start 2015-01 · primary completion 2015-05 | Phase 1Completed | Attention-deficit Hyperactivity Disorder (ADHD) | Aevi Genomic Medicine, LLC, a Cerecor company30 participants |
Registry check 2026-10-09 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received Fasoracetam, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
- Human study · PubMed trial index Compound given to participants
Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling.
Elia J, Ungal G, Kao C et al. · Nature communications · 2018
PMID 29339723 · DOI: 10.1038/s41467-017-02244-2 · Registration NCT02286817
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Research publication · design requires review
Fasoracetam. LAM 105, NS 105.
· Drugs in R&D · 1999
PMID 10820660 · DOI: 10.2165/00126839-199902020-00014
- Research publication · design requires review
A Study of Fasoracetam's Solid State Forms: A Potential Anti-Alzheimer Pharmaceutical.
Harmsen B, Robeyns K, Wouters J et al. · Journal of pharmaceutical sciences · 2017
PMID 28109793 · DOI: 10.1016/j.xphs.2017.01.016
Fasoracetam Powder supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Fasoracetam Powder for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Amino USAUSD | 1000mg Powder · 5000mg Powder2 recorded offers | 1000mg Powder · $16.00Checked Nov 6, 2026Supplier listing, Fasoracetam Powder 1000mg Powder, Amino USA, opens in a new tab |
Reference sources & further reading
- PubChem compound record 198695 — chemical identity and structure.
- ChEMBL drug record CHEMBL2106179 — development stage, mechanism and synonyms.
- FDA Global Substance Registration System: UNII 42O8UF5CJB — substance identity, names and codes.
- Wikipedia: Fasoracetam — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Adalank Spray
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Adamax
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Adamax 1032 Spray
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Agomelatine Powder
C15H17NO2
243.30 g/mol · PubChem CID 82148
8 selected publications · 5 human intervention studies · 19 registered trials
Small molecule · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Cerebrolysin
Molecular identity needs further verification
7 selected publications · 5 human intervention studies · 40 registered trials
Dihexa
C27H44N4O5
504.7 g/mol · PubChem CID 129010512
2 selected publications · 0 human intervention studies